POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

Swissmedic approves extension of booster dose to everyone aged 16 years and over

Christian Fernsby |
After reviewing the recently submitted data, Swissmedic is adapting the information for healthcare professionals for the COVID-19 mRNA vaccine from Pfizer BioNTech (Comirnaty).

Article continues below

This clears the way for wider use of the booster vaccination. High risk individuals can still obtain a booster dose from age 12.

Swissmedic has reviewed the documentation submitted by the marketing authorisation holder last week and is adapting the product information. Individuals aged 16 years and over can now be administered a booster dose.

As stipulated in the Swissmedic decision of 26 October 2021, high risk individuals can still obtain the booster from age 12. In both cases, however, the second dose must have been administered at least six months previously.

Swissmedic reached this decision based, among other factors, on a study with 10,000 participants aged 16 to 87. The interim results of this study gave no indication of new risk aspects for the vaccine. Basic immunisation with Comirnaty involves two doses of 0.3 ml administered at an interval of three weeks.

The booster vaccination at least six months later that has now been approved can maintain protection against COVID-19 disease.

What to read next

Swissmedic approves third vaccination for certain population groups
EMA authorised Spikevax for use as a booster shot for 18 years old and above
Pfizer makes progress with COVID vaccine for children, Lyme disease vaccine candidate